N-Acetyl Semax

1. Overview

N-Acetyl Semax is a chemically modified derivative of Semax, the synthetic heptapeptide nootropic and neuroprotective agent developed at the Institute of Molecular Genetics of the Russian Academy of Sciences [4][11]. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was designed as a stabilized analog of the ACTH(4-10) fragment -- the portion of adrenocorticotropic hormone responsible for cognitive and neurotrophic effects, deliberately truncated from the hormone's steroidogenic domain to eliminate cortisol-stimulating activity [11]. Semax was approved in Russia for treatment of acute ischemic stroke (at 1% concentration) and cognitive enhancement (at 0.1% concentration), both administered intranasally [3][4].

The N-acetyl modification involves covalent attachment of an acetyl group to the alpha-amino group of the N-terminal methionine residue. This well-established pharmaceutical modification protects the peptide from aminopeptidase-mediated degradation, the primary route of catabolism for small peptides in plasma and at tissue surfaces [13]. Unmodified Semax has a plasma half-life of only several minutes, necessitating frequent intranasal dosing; the acetylated form is designed to extend this half-life, potentially improving CNS bioavailability and therapeutic convenience [12].

The pharmacological profile of N-Acetyl Semax is expected to be qualitatively identical to that of Semax, encompassing upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), neuroprotection against ischemic injury, enhancement of attention and memory, and modulation of dopaminergic, serotonergic, and cholinergic neurotransmission [1][5][8]. The acetylation is a pharmacokinetic enhancement rather than a pharmacodynamic modification.

N-Acetyl Semax has not been independently evaluated in published clinical trials. Its pharmacological profile is inferred from the extensive Semax literature.

Parent Peptide

Semax (Met-Glu-His-Phe-Pro-Gly-Pro)

Modification

N-terminal acetylation (Ac-Met-Glu-His-Phe-Pro-Gly-Pro)

Molecular Weight

~855.97 Da

Parent Sequence Origin

ACTH(4-10) with C-terminal Pro-Gly-Pro extension

Half-life

Extended vs. Semax (several minutes); exact value not published

Routes Studied

Intranasal, subcutaneous

FDA Status

Not approved outside Russia; Semax approved in Russia

Key Advantage

Enhanced metabolic stability and potentially prolonged nootropic effects

2. Mechanism of Action

The mechanism of action of N-Acetyl Semax is expected to be identical to that of unmodified Semax, as the N-terminal acetylation does not alter the peptide's interaction with its biological targets.

Neurotrophic Factor Upregulation

The most extensively documented mechanism of Semax involves upregulation of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF). Eremin et al. (2005) demonstrated that intranasal Semax significantly increased BDNF mRNA expression in the rat hippocampus and basal forebrain within 30 minutes of administration [1]. Dolotov et al. (2006) confirmed that Semax increased both BDNF and its receptor TrkB expression, and promoted survival of cholinergic neurons -- the neuronal population most severely affected in Alzheimer's disease [5].

Dolotov et al. (2003) showed that Semax altered the NGF/BDNF ratio in the hippocampus, with BDNF levels increasing significantly [8]. These neurotrophic changes were independent of ACTH-like hormonal effects, confirming the separation of cognitive and steroidogenic activities in Semax's design.

Neuroprotection in Ischemia

Semax has demonstrated robust neuroprotective effects in cerebral ischemia models. Levitskaya et al. (2004) showed prevention of neuronal death in the hippocampal CA1 region following transient global ischemia [2]. Medvedeva et al. (2014) used transcriptomic analysis to reveal that Semax modulated expression of genes involved in immune response, apoptosis, and vascular regulation within 3-24 hours of ischemic injury [7]. Agapova et al. (2007) demonstrated modulation of calcium signaling and neuroinflammatory gene expression patterns during ischemia [6].

Neurotransmitter Modulation

Semax modulates multiple neurotransmitter systems relevant to cognition:

• Dopaminergic system: Enhanced dopamine release and signaling in forebrain regions
• Serotonergic system: Modulation of 5-HT metabolism
• Cholinergic system: Promotion of cholinergic neuron survival and function [5][10]

Neuroimaging Evidence

Ershov et al. (2020) demonstrated that Semax altered resting-state functional connectivity patterns in healthy human volunteers within 20 minutes of intranasal administration, providing fMRI evidence of rapid central effects [9].

3. The N-Acetyl Modification

Rationale

The primary degradation pathway for Semax in biological fluids is aminopeptidase-mediated cleavage from the N-terminus [13]. The methionine residue at position 1 is particularly vulnerable, and its removal initiates sequential degradation of the entire peptide. N-terminal acetylation blocks this degradation pathway by capping the free amino group, rendering it unrecognizable to aminopeptidases.

Expected Effects

• Extended half-life: Reduced aminopeptidase susceptibility should prolong plasma and tissue residence time
• Enhanced BBB penetration: Greater stability during transit allows more peptide to reach the CNS [12]
• Reduced dosing frequency: Longer duration of action may allow less frequent administration
• Preserved activity: The ACTH(4-10)-derived pharmacophore remains intact

Comparison with Unmodified Semax

The key distinction is pharmacokinetic. N-Acetyl Semax is expected to produce more sustained neurotrophic factor upregulation, more prolonged neuroprotective effects, and potentially greater CNS accumulation after each dose compared to unmodified Semax. The qualitative pharmacological profile -- the types of effects produced -- should be identical.

4. Researched Applications

Cognitive Enhancement

Evidence level: Moderate (clinical trials with Semax)

Kaplan et al. (1996) demonstrated in a randomized clinical trial that Semax improved attention and short-term memory performance in healthy human volunteers [4]. These nootropic effects are attributed to BDNF upregulation and cholinergic system enhancement. N-Acetyl Semax would be expected to produce the same cognitive benefits with potentially longer duration.

Stroke and Ischemic Brain Injury

Evidence level: Moderate (clinical trials with Semax)

Gusev et al. (2005) conducted a randomized trial in 100 patients with acute ischemic stroke, finding that intranasal Semax (12 mg/day for 5 days) accelerated neurological recovery compared to placebo [3]. The neuroprotective mechanism involves BDNF/NGF upregulation, anti-apoptotic gene activation, and modulation of neuroinflammatory pathways [2][7].

Neurodevelopment and Neural Differentiation

Evidence level: Preliminary (in vitro)

Grivennikov et al. (2008) demonstrated that Semax promoted differentiation and neurite outgrowth in embryonic brain neurons in culture [10], suggesting potential applications in neurodevelopmental and neuroregenerative contexts.

Spinal Cord Injury (Emerging 2025 Research)

Evidence level: Preliminary (preclinical)

A 2025 study published in the British Journal of Pharmacology demonstrated that Semax improved functional recovery after spinal cord injury in female mice by targeting the mu-opioid receptor gene Oprm1. Semax inhibited lysosomal membrane permeabilization (LMP)-related pyroptosis by decreasing oxidative stress and promoted functional recovery by regulating USP18 and subsequent deubiquitination pathways. This represents a novel mechanism of action for Semax distinct from its previously characterized BDNF/NGF upregulation.

Alzheimer's Disease (Emerging 2025 Research)

Evidence level: Preliminary (preclinical)

A 2025 study assessed the effects of Semax and a derivative peptide on behavioral characteristics in transgenic mouse models of Alzheimer's disease, reporting improvements in cognitive function. A preliminary cohort of AD patients also showed signals of benefit, though the investigators noted that further detailed investigation is required before broader clinical application.

5. Clinical Evidence Summary

6. Dosing in Research

Dosing protocols specific to N-Acetyl Semax have not been published. The following reflects Semax dosing from clinical studies. Enhanced stability of the acetylated form may permit lower doses.

7. Safety and Side Effects

Semax has demonstrated a favorable safety profile in clinical use in Russia, with no significant adverse effects reported in stroke trials at doses up to 12 mg/day [3]. The peptide was specifically designed to eliminate ACTH's steroidogenic activity -- Semax does not stimulate cortisol release or affect the adrenal axis at therapeutic doses [11].

N-Acetyl Semax is expected to share this safety profile. The acetylation does not introduce novel pharmacological activity, and the acetyl group itself is metabolically inert at the quantities present. However, the extended half-life means that any adverse effects could potentially persist longer than with unmodified Semax.

No specific safety data has been published for N-Acetyl Semax. Areas of uncertainty include long-term effects on neurotrophic factor signaling, potential interactions with other CNS-active medications, and effects in special populations (pregnancy, pediatric, elderly with neurodegenerative disease).

8. Pharmacokinetics

Unmodified Semax Pharmacokinetics

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) has a plasma half-life of only several minutes after systemic administration, consistent with its small size (855.97 Da for the free peptide) and susceptibility to plasma aminopeptidases [13]. The rapid clearance necessitates intranasal administration for clinical use, which provides more direct CNS access via the olfactory and trigeminal nerve pathways while partially bypassing hepatic first-pass metabolism [3][12].

N-terminal vulnerability: The methionine residue at position 1 is particularly susceptible to aminopeptidase cleavage. Methionine is also vulnerable to oxidation (forming methionine sulfoxide), which can further alter the peptide's biological activity and accelerate degradation.

Intranasal pharmacokinetics (clinical use):

• Russian clinical protocols use 0.1% solution (cognitive enhancement) or 1% solution (stroke) administered intranasally
• Rapid CNS penetration demonstrated by Ershov et al. (2020), with fMRI-detectable functional connectivity changes within 20 minutes of intranasal Semax [9]
• Eremin et al. (2005) showed BDNF mRNA upregulation in rat hippocampus within 30 minutes of intranasal administration [1]
• Dosing frequency: 2-3 times daily for cognitive enhancement; more frequently for acute stroke (12 mg/day for 5 days) [3][4]

N-Acetyl Semax Enhanced Pharmacokinetics

The N-terminal acetylation addresses Semax's primary pharmacokinetic limitation [13]:

Aminopeptidase resistance: The acetyl group on the N-terminal methionine blocks recognition by aminopeptidases, eliminating the dominant degradation pathway. This is particularly effective for Semax because the Met residue is the most vulnerable point in the sequence.

Methionine oxidation protection: Acetylation may provide partial protection against methionine oxidation by altering the electronic environment of the sulfur atom, though this effect is less established than the aminopeptidase resistance.

Expected half-life extension: Based on analogous N-terminal acetylation of other short peptides, N-Acetyl Semax is expected to have a half-life approximately 3-10 fold longer than unmodified Semax. This projects to a half-life in the range of 15-60 minutes -- a meaningful improvement for CNS bioavailability.

Enhanced BBB penetration: Two factors improve blood-brain barrier transit [12]:

• Greater metabolic stability means more intact peptide reaches the BBB during transit from the nasal mucosa or systemic circulation
• Reduced N-terminal positive charge (acetylation eliminates the free amino group charge) may improve passive diffusion across the lipid bilayer

Sustained neurotrophic effects: The extended presence of active peptide is expected to produce more sustained BDNF/NGF upregulation per dose, potentially amplifying the neurotrophic and neuroprotective effects that are central to Semax's mechanism of action [1][5][8].

CNS Pharmacodynamic Timeline

Based on Semax data, the pharmacodynamic timeline for CNS effects is:

• 20 minutes: Functional connectivity changes detectable on fMRI [9]
• 30 minutes: BDNF mRNA upregulation in hippocampus [1]
• 1-3 hours: Peak neurotrophic factor protein expression
• 3-24 hours: Downstream gene expression changes in ischemia models (immune response, apoptosis, vascular genes) [7]

N-Acetyl Semax's extended half-life would be expected to shift and broaden this timeline, with potentially greater peak effects and more sustained downstream signaling.

9. Dose-Response Relationships

Nootropic Dose-Response (Semax Data)

Kaplan et al. (1996) -- Cognitive Enhancement in Healthy Volunteers: Semax (intranasal, 0.1% solution) improved attention and short-term memory performance in a randomized controlled trial [4]. The cognitive enhancement was observed at standard clinical doses (200-600 mcg, 2-3 times daily).

Neuroprotective Dose-Response

Stroke (Gusev et al. 2005):

• 12 mg/day intranasal (1% solution) for 5 days: Accelerated neurological recovery in 100 patients with acute ischemic stroke compared to placebo [3]
• This high dose (approximately 100-fold higher than cognitive enhancement doses) reflects the acute, high-dose neuroprotective application versus the lower chronic nootropic use
• The dose differential between cognitive enhancement (hundreds of micrograms) and stroke neuroprotection (milligrams) suggests different dose-effect thresholds for nootropic versus neuroprotective applications

Ischemia model (Levitskaya et al. 2004): Semax prevented hippocampal CA1 neuronal death following transient global ischemia in gerbils, with protection observed at doses in the microgram-per-kilogram range [2].

BDNF Upregulation Dose-Response

Eremin et al. (2005) and Dolotov et al. (2003, 2006) demonstrated dose-dependent BDNF upregulation [1][5][8]:

• Intranasal Semax increased BDNF mRNA in the hippocampus and basal forebrain
• BDNF and TrkB receptor expression were both upregulated
• The NGF/BDNF ratio shifted toward BDNF dominance
• Effects were independent of ACTH-like hormonal activity (confirming separation of cognitive and steroidogenic functions in Semax's design)

Projected N-Acetyl Semax Dose-Response

Enhanced metabolic stability predicts that N-Acetyl Semax will achieve equivalent effects at lower doses than Semax:

• Greater fraction of each dose reaches CNS targets intact
• Longer duration of BDNF/NGF upregulation per dose
• Potential for reduced dosing frequency (once or twice daily vs. 2-3 times daily)
• Exact dose equivalence ratios have not been established in published research

10. Comparative Effectiveness

N-Acetyl Semax vs. Semax

| Parameter | N-Acetyl Semax | Semax | |---|---|---| | Sequence | Ac-Met-Glu-His-Phe-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro | | Half-life | Extended (estimated 3-10x longer) | Several minutes | | BBB penetration | Potentially improved | Standard (intranasal route) | | Dosing frequency | Potentially reduced | 2-3 times daily (cognitive); frequent (stroke) | | BDNF upregulation | Expected equivalent or enhanced (longer exposure) | Demonstrated in multiple studies | | Neuroprotection | Expected equivalent or enhanced | Demonstrated (stroke, ischemia models) | | Cognitive enhancement | Expected equivalent | Demonstrated (RCT in healthy volunteers) | | Clinical evidence | None (independent trials) | Russian approval; clinical trials (stroke, cognition) | | Regulatory status | Not approved anywhere | Approved in Russia (intranasal) |

N-Acetyl Semax vs. N-Acetyl Selank

Both are acetylated derivatives of Russian-developed therapeutic peptides:

| Parameter | N-Acetyl Semax | N-Acetyl Selank | |---|---|---| | Parent peptide | Semax (ACTH 4-10 analog) | Selank (tuftsin analog) | | Primary effect | Nootropic / neuroprotective | Anxiolytic / nootropic | | Key mechanism | BDNF/NGF upregulation | GABAergic modulation, serotonergic effects | | Best suited for | Cognitive enhancement, stroke recovery | Anxiety, stress-related conditions | | CNS target | Hippocampus, basal forebrain (memory circuits) | Amygdala, temporal cortex (anxiety circuits) | | Immunomodulation | Minimal | Significant (tuftsin-derived) | | Steroidogenic activity | None (deliberately eliminated from ACTH design) | None | | Complementarity | Can be combined with N-Acetyl Selank | Can be combined with N-Acetyl Semax |

N-Acetyl Semax vs. Racetams (Piracetam, Aniracetam)

| Parameter | N-Acetyl Semax | Racetams | |---|---|---| | Class | Peptide nootropic | Small-molecule nootropics | | Mechanism | BDNF/NGF neurotrophic upregulation | AMPA receptor modulation, cholinergic effects | | Administration | Intranasal (peptide) | Oral (small molecule) | | Onset | Rapid (20-30 min CNS effects) | Variable (30-60 min) | | Neuroprotection | Strong (stroke clinical data with Semax) | Modest (primarily cognitive, less neuroprotective) | | Neurotrophic effects | Robust BDNF/NGF upregulation | Minimal direct neurotrophic effects | | Clinical evidence | Approved in Russia for stroke and cognition | Mixed (piracetam has extensive but inconsistent data) |

N-Acetyl Semax vs. Dihexa

Both are peptide-based nootropic agents targeting neurotrophic pathways:

• Dihexa acts through HGF/c-Met pathway (hepatocyte growth factor)
• N-Acetyl Semax acts through BDNF/NGF pathways
• Different neurotrophic factor targets may provide complementary mechanisms
• N-Acetyl Semax (via Semax) has substantially more clinical evidence

11. Enhanced Safety Profile

Semax-Based Safety Data

Semax has demonstrated a favorable safety profile across extensive clinical use in Russia [3][4][11]:

No steroidogenic activity: Semax was specifically designed to retain the cognitive effects of ACTH(4-10) while eliminating ACTH's steroidogenic (cortisol-stimulating) activity. The truncation from ACTH and addition of the Pro-Gly-Pro stabilizing sequence completely eliminates adrenal axis stimulation [11]. N-Acetyl Semax inherits this key safety feature.

Stroke trial safety (Gusev et al. 2005): In 100 patients with acute ischemic stroke receiving high-dose intranasal Semax (12 mg/day for 5 days), no significant adverse effects were reported [3]. The absence of safety signals even at these high doses in acutely ill patients is reassuring.

Cognitive enhancement safety (Kaplan et al. 1996): No adverse effects reported at standard nootropic doses in healthy volunteers [4].

Neuroimaging safety (Ershov et al. 2020): In 52 healthy subjects receiving intranasal Semax, no adverse effects were reported during or after the fMRI study [9].

N-Acetyl Modification Safety

The N-terminal acetylation does not introduce novel pharmacological activity [13]:

• The acetyl group is metabolically inert at the microgram quantities present in each dose
• N-acetylation is a ubiquitous biological modification (approximately 80-90% of eukaryotic cytoplasmic proteins are N-terminally acetylated)
• No specific safety concerns are associated with N-acetylated peptide therapeutics
• The modification preserves the entire ACTH(4-10)-derived pharmacophore

Extended Duration Considerations

The enhanced stability of N-Acetyl Semax means that both therapeutic effects and any potential adverse effects would persist longer per dose. Key implications:

• Beneficial: More sustained BDNF upregulation and neuroprotection per dose
• Consideration: If a patient experienced an unusual reaction, the effects would take longer to resolve than with unmodified Semax
• Mitigation: Given Semax's clean safety profile across decades of clinical use, extended duration is unlikely to unmask significant new adverse effects

Areas of Uncertainty

Long-term neurotrophic factor modulation: Chronic upregulation of BDNF/NGF has theoretical implications for neural plasticity and potentially for tumor biology (some brain tumors express neurotrophin receptors). No evidence of harm has been observed, but long-term surveillance data is limited.

Drug interactions: Formal interaction studies have not been conducted. Potential interactions include:

• Other nootropic agents (additive cognitive effects)
• Dopaminergic medications (Semax modulates dopamine signaling)
• Serotonergic medications (Semax modulates 5-HT metabolism)
• Anticoagulants (Semax modulates vascular gene expression in ischemia)

Special populations: Safety in pregnancy, pediatric populations, and elderly with neurodegenerative disease has not been established for either Semax or N-Acetyl Semax.

Purity and quality: Commercially available N-Acetyl Semax is manufactured outside pharmaceutical regulatory oversight, with standard concerns about purity, accurate peptide content, and potential contamination.

12. Related Peptides

See also: Semax, Selank, N-Acetyl Semax Amidate, Noopept

13. References

1. [1] Eremin KO, Kudrin VS, Saranseva SE, et al. (2005). Semax, an ACTH(4-10) analog with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents. Neurochem Res. PubMed
2. [2] Levitskaya NG, Vilkov GA, Makarov VL, et al. (2004). Neuroprotective effects of semax in incomplete global cerebral ischemia. Bull Exp Biol Med. PubMed
3. [3] Gusev EI, Skvortsova VI, Izhboldina GI, et al. (2005). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. PubMed
4. [4] Kaplan AY, Kochetova AG, Nezavibatko VN, et al. (1996). Synthetic ACTH analogue semax displays nootropic-like activity in humans. Neurosci Res Commun. PubMed
5. [5] Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive enhancing properties, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. PubMed
6. [6] Agapova TYu, Agniullin YV, Silachev DN, et al. (2007). Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus. Dokl Biol Sci. PubMed
7. [7] Medvedeva EV, Dmitrieva VG, Limborska SA, et al. (2014). Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. PubMed
8. [8] Dolotov OV, Karpenko EA, Seredenina TS, et al. (2003). Semax increases expression of BDNF gene and its receptor TrkB in rat hippocampus after transient forebrain ischemia. Dokl Biochem Biophys. PubMed
9. [9] Ershov FI, Uchakin PN, Ershova OA, et al. (2020). Functional connectomic study of the effects of selank and semax on resting brain activity. Hum Brain Mapp. PubMed
10. [10] Grivennikov IA, Dolotov OV, Goldina YI (2008). Peptide drugs of neurotrophin superfamily. Neurochem J. PubMed
11. [11] Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. (1995). Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and hydrophobic radicals. Neurosci Res Commun.
12. [12] Banks WA (2015). Peptides and the blood-brain barrier. Peptides. DOI PubMed
13. [13] Powell JT, Bhatt TK (2011). N-alpha-terminal acetylation of proteins. Nat Rev Mol Cell Biol. PubMed